Camlin Fine Sciences · NSE: CAMLINFINE · BSE: 532834
Q2 FY26 results · Jul–Sep 2025
Camlin Fine Sciences reported revenue from operations of ₹459.83 crore (up 8.7% from Q2 FY25) and net loss of ₹14.95 crore for Q2 FY26 (Jul–Sep 2025), on a consolidated basis.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 459.83 | 422.97 | +8.7% | 423.55 | +8.6% |
| Other income | 4.59 | 12.10 | −62.1% | 8.56 | −46.4% |
| Total income | 464.42 | 435.07 | +6.7% | 432.12 | +7.5% |
| Profit before share of associates & JVs and tax | 0.27 | (142.81) | Turned profit | (5.15) | Turned profit |
| Share of profit/(loss) of associates & JVs | (0.36) | 0.51 | 0.89 | ||
| Net profit for the period | (14.95) | (116.11) | Loss narrowed | (10.68) | Loss widened |
| Attributable to shareholders of the company | (14.38) | (100.23) | Loss narrowed | (9.96) | Loss widened |
| EPS, basic (₹) | (0.76) | (5.98) | not comparable | (0.53) | Loss widened |
| Net margin (%) | -3.3 | -27.5 | -2.5 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY26 | Q2 FY25 | YoY | Q1 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 244.04 | 226.91 | +7.5% | 191.44 | +27.5% |
| Other income | 10.19 | 3.08 | +230.8% | 3.69 | +176.3% |
| Total income | 254.24 | 229.99 | +10.5% | 195.13 | +30.3% |
| Profit before tax | (3.81) | (110.54) | Loss narrowed | (16.38) | Loss narrowed |
| Net profit for the period | (3.64) | (72.62) | Loss narrowed | (10.68) | Loss narrowed |
| EPS, basic (₹) | (0.19) | (4.34) | not comparable | (0.57) | Loss narrowed |
| Net margin (%) | -1.5 | -32.0 | -5.6 |
Consolidated
- Filed with BSE
- 10 Nov 2025, 19:47 IST
- Board meeting
- 10 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 10 Nov 2025, 19:47 IST
- Board meeting
- 10 Nov 2025
- Period
- 01 Jul 2025 to 30 Sep 2025
- Review status
- Unaudited
- Source
- XBRL filing on BSE